Open AccessControl of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day
Author(s) -
Søren Pedersen,
Niyati Prasad,
Udo Michael Goehring,
Henrik Andersson,
Dirkje S. Postma
Publication year - 2017
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s111712
Subject(s) - medicine , ciclesonide , asthma , randomized controlled trial , anesthesia , inhaled corticosteroids
The inhaled corticoteroid (ICS) ciclesonide (Cic), controls asthma symptoms in the majority of patients at the recommended dose of 160 µg/day. However, the relationship between the level of asthma control and increasing doses of Cic is unknown. This study investigated whether long-term treatment with higher doses of Cic would further improve asthma symptoms in patients with uncontrolled asthma despite ICS use.